BNP Paribas Financial Markets’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $81.6M | Sell |
271,023
-9,942
| -4% | -$3M | 0.03% | 539 |
|
|
2026
Q1 | $93M | Sell |
280,965
-108,470
| -28% | -$36.9M | 0.05% | 437 |
|
|
2025
Q4 | $155M | Buy |
389,435
+236,396
| +154% | +$105M | 0.07% | 259 |
|
|
2025
Q3 | $69.8M | Buy |
153,039
+24,405
| +19% | +$9.94M | 0.04% | 485 |
|
|
2025
Q2 | $41.9M | Buy |
128,634
+86,059
| +202% | +$23.8M | 0.02% | 660 |
|
|
2025
Q1 | $11.5M | Buy |
42,575
+857
| +2% | +$220K | 0.01% | 1334 |
|
|
2024
Q4 | $9.82M | Sell |
41,718
-73,066
| -64% | -$19.2M | 0.01% | 1373 |
|
|
2024
Q3 | $31.6M | Sell |
114,784
-11,228
| -9% | -$2.92M | 0.02% | 677 |
|
|
2024
Q2 | $30.6M | Buy |
126,012
+24,566
| +24% | +$3.88M | 0.03% | 589 |
|
|
2024
Q1 | $15.2M | Buy |
101,446
+18,742
| +23% | +$3.13M | 0.01% | 899 |
|
|
2023
Q4 | $15.8M | Buy |
82,704
+31,301
| +61% | +$5.33M | 0.02% | 810 |
|
|
2023
Q3 | $9.1M | Buy |
51,403
+12,822
| +33% | +$2.45M | 0.01% | 943 |
|
|
2023
Q2 | $7.33M | Sell |
38,581
-32,502
| -46% | -$6.44M | 0.01% | 1040 |
|
|
2023
Q1 | $14.2M | Buy |
71,083
+42,972
| +153% | +$9.03M | 0.02% | 739 |
|
|
2022
Q4 | $6.68M | Sell |
28,111
-61,239
| -69% | -$13.1M | 0.01% | 1166 |
|
|
2022
Q3 | $17.9M | Buy |
89,350
+32,229
| +56% | +$6.15M | 0.03% | 684 |
|
|
2022
Q2 | $8.33M | Sell |
57,121
-9,579
| -14% | -$1.36M | 0.01% | 995 |
|
|
2022
Q1 | $10.9M | Buy |
66,700
+681
| +1% | +$104K | 0.01% | 886 |
|
|
2021
Q4 | $11.2M | Sell |
66,019
-11,162
| -14% | -$2.07M | 0.02% | 910 |
|
|
2021
Q3 | $14.6M | Buy |
77,181
+57,144
| +285% | +$10.7M | 0.02% | 753 |
|
|
2021
Q2 | $3.4M | Sell |
20,037
-3,958
| -16% | -$580K | ﹤0.01% | 1502 |
|
|
2021
Q1 | $3.39M | Sell |
23,995
-14,050
| -37% | -$2.11M | 0.01% | 1388 |
|
|
2020
Q4 | $4.94M | Buy |
38,045
+1,184
| +3% | +$158K | 0.01% | 1140 |
|
|
2020
Q3 | $5.37M | Sell |
36,861
-14,099
| -28% | -$2M | 0.01% | 1052 |
|
|
2020
Q2 | $7.55M | Sell |
50,960
-4,209
| -8% | -$567K | 0.01% | 841 |
|
|
2020
Q1 | $6.01M | Sell |
55,169
-27,553
| -33% | -$3.18M | 0.01% | 897 |
|
|
2019
Q4 | $9.53M | Buy |
82,722
+36,448
| +79% | +$3.63M | 0.02% | 867 |
|
|
2019
Q3 | $3.72M | Sell |
46,274
-1,681
| -4% | -$133K | 0.01% | 1209 |
|
|
2019
Q2 | $3.48M | Buy |
47,955
+9,884
| +26% | +$758K | 0.01% | 1204 |
|
|
2019
Q1 | $3.56M | Sell |
38,071
-3,898
| -9% | -$326K | 0.01% | 1131 |
|
|
2018
Q4 | $3.06M | Buy |
41,969
+14,163
| +51% | +$1.09M | 0.01% | 1124 |
|
|
2018
Q3 | $2.43M | Buy |
27,806
+9,562
| +52% | +$962K | ﹤0.01% | 1415 |
|
|
2018
Q2 | $1.8M | Buy |
18,244
+2,870
| +19% | +$285K | ﹤0.01% | 1522 |
|
|
2018
Q1 | $1.83M | Buy |
15,374
+3,298
| +27% | +$425K | ﹤0.01% | 1432 |
|
|
2017
Q4 | $1.53M | Buy |
12,076
+2,579
| +27% | +$324K | ﹤0.01% | 1663 |
|
|
2017
Q3 | $1.12M | Sell |
9,497
-3,503
| -27% | -$299K | ﹤0.01% | 1492 |
|
|
2017
Q2 | $1.04M | Sell |
13,000
-2,043
| -14% | -$131K | ﹤0.01% | 1514 |
|
|
2017
Q1 | $771K | Sell |
15,043
-728
| -5% | -$33.6K | ﹤0.01% | 1494 |
|
|
2016
Q4 | $590K | Buy |
15,771
+5,231
| +50% | +$219K | ﹤0.01% | 1608 |
|
|
2016
Q3 | $714K | Sell |
10,540
-586
| -5% | -$41.3K | ﹤0.01% | 1046 |
|
|
2016
Q2 | $617K | Buy |
11,126
+2,156
| +24% | +$136K | ﹤0.01% | 1403 |
|
|
2016
Q1 | $563K | Buy |
8,970
+1,155
| +15% | +$76.8K | ﹤0.01% | 1169 |
|
|
2015
Q4 | $736K | Sell |
7,815
-2,968
| -28% | -$275K | ﹤0.01% | 1002 |
|
|
2015
Q3 | $867K | Sell |
10,783
-78,631
| -88% | -$8.74M | ﹤0.01% | 1093 |
|
|
2015
Q2 | $10.7M | Buy |
89,414
+85,127
| +1,986% | +$10.2M | 0.03% | 346 |
|
|
2015
Q1 | $448K | Buy |
4,287
+2,223
| +108% | +$225K | ﹤0.01% | 1351 |
|
|
2014
Q4 | $200K | Buy |
2,064
+64
| +3% | +$5.93K | ﹤0.01% | 1359 |
|
|
2014
Q3 | $156K | Sell |
2,000
-134
| -6% | -$8.64K | ﹤0.01% | 1980 |
|
|
2014
Q2 | $135K | Buy |
2,134
+1,134
| +113% | +$67.4K | ﹤0.01% | 1921 |
|
|
2014
Q1 | $49.5K | Buy |
1,000
+246
| +33% | +$19K | ﹤0.01% | 2131 |
|
|
2013
Q4 | $48.5K | Sell |
754
-15,205
| -95% | -$907K | ﹤0.01% | 1932 |
|
|
2013
Q3 | $1.02M | Sell |
15,959
-4,443
| -22% | -$221K | ﹤0.01% | 1127 |
|
|
2013
Q2 | $633K | Buy |
+20,402
| New | +$543K | ﹤0.01% | 1337 |
|
Other funds holding ALNY
BNP Paribas Financial Markets's ALNY Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.5% in Q2 2026, selling an estimated $3M and leaving 271,023 shares worth $81.6M. The position accounts for 0.03% of the portfolio, ranked #539.
BNP Paribas Financial Markets first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $155M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- BNP Paribas Financial Markets held 271,023 shares of Alnylam Pharmaceuticals worth $81.6M as of Q2 2026.
- BNP Paribas Financial Markets sold 9,942 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $3M.
- Alnylam Pharmaceuticals made up 0.03% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #539 holding.
- BNP Paribas Financial Markets first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- BNP Paribas Financial Markets's Alnylam Pharmaceuticals position peaked at $155M in Q4 2025.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.